Yang Xudan, Xu Zhihao, Hu Songhua, Shen Juan
Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, China.
Front Pharmacol. 2023 Feb 14;14:1111393. doi: 10.3389/fphar.2023.1111393. eCollection 2023.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3-5 years. Currently approved drugs for the treatment of IPF are Pirfenidone and Nintedanib, as antifibrotic drugs, which can reduce the decline rate of forced vital capacity (FVC) and reduce the risk of acute exacerbation of IPF. However these drugs can not relieve the symptoms associated with IPF, nor improve the overall survival rate of IPF patients. We need to develop new, safe and effective drugs to treat pulmonary fibrosis. Previous studies have shown that cyclic nucleotides participate in the pathway and play an essential role in the process of pulmonary fibrosis. Phosphodiesterase (PDEs) is involved in cyclic nucleotide metabolism, so PDE inhibitors are candidates for pulmonary fibrosis. This paper reviews the research progress of PDE inhibitors related to pulmonary fibrosis, so as to provide ideas for the development of anti-pulmonary fibrosis drugs.
特发性肺纤维化（IPF）是一种病因不明的慢性进行性间质性肺疾病（ILD）。诊断后若不进行治疗，平均预期寿命为3至5年。目前批准用于治疗IPF的药物是吡非尼酮和尼达尼布，作为抗纤维化药物，它们可以降低用力肺活量（FVC）的下降速率，并降低IPF急性加重的风险。然而，这些药物不能缓解与IPF相关的症状，也不能提高IPF患者的总体生存率。我们需要研发新的、安全有效的药物来治疗肺纤维化。先前的研究表明，环核苷酸参与该途径并在肺纤维化过程中起重要作用。磷酸二酯酶（PDEs）参与环核苷酸代谢，因此PDE抑制剂是治疗肺纤维化的候选药物。本文综述了与肺纤维化相关的PDE抑制剂的研究进展，以期为抗肺纤维化药物的研发提供思路。
